Thrombosis research · 2025
Characterization of a novel factor X variant, p.F139L, associated with bleedings in heterozygous and compound heterozygous form.
СтатьяКлинический случайПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hellum Marit, Sletten Marit, Le Marie S, Stavseth Vidar, Glosli Heidi, Backe Paul Hoff, Iversen Nina, Henriksson Carola E
Аннотация
INTRODUCTION: Congenital factor X (FX) deficiency is a rare bleeding disorder. Heterozygous patients may experience bleedings like epistaxis or bleeding complications after dental extraction and surgery, whereas homozygous individuals often experience more severe bleedings.
AIM: To characterize a new FX variant found in two unrelated probands with mild to moderate bleeding tendencies.
METHODS: Prothrombin time (PT) Quick, APTT, FX activity, FX antigen, thrombin generation and DNA sequencing were performed for probands and their families. F10 variants were explored in programs for in silico predictions and structural analyses, and in vitro expression was used for further characterization.
RESULTS: A novel missense variant (c.415T>C, p.F139L) was found in heterozygous form in proband 1 and in compound heterozygous form in proband 2, in combination with a previously known missense variant (c.424G>A, p.E142K). All individuals carrying the p.F139L variant had borderline/prolonged PT Quick (11.9-15.9 s) and APTT (36-43 s) and reduced thrombin generation. Both FX antigen (30-51 %) and activity (37-63 IU/dL) were reduced, indicating a type I deficiency. Structural analysis indicated that interactions between the EGF-2 and the protease domain of FX could be disrupted in the p.F139L variant, causing destabilization of the protein. The p.E142K variant was predicted to have less impact on FX structure. In vitro expression results further supported plasma findings.
CONCLUSION: We report a new FX variant, p.F139L, causing a type I FX deficiency associated with mild to moderate bleedings in heterozygous and compound heterozygous form. The variant causes structural changes which likely affect intracellular processing of FX.
AIM: To characterize a new FX variant found in two unrelated probands with mild to moderate bleeding tendencies.
METHODS: Prothrombin time (PT) Quick, APTT, FX activity, FX antigen, thrombin generation and DNA sequencing were performed for probands and their families. F10 variants were explored in programs for in silico predictions and structural analyses, and in vitro expression was used for further characterization.
RESULTS: A novel missense variant (c.415T>C, p.F139L) was found in heterozygous form in proband 1 and in compound heterozygous form in proband 2, in combination with a previously known missense variant (c.424G>A, p.E142K). All individuals carrying the p.F139L variant had borderline/prolonged PT Quick (11.9-15.9 s) and APTT (36-43 s) and reduced thrombin generation. Both FX antigen (30-51 %) and activity (37-63 IU/dL) were reduced, indicating a type I deficiency. Structural analysis indicated that interactions between the EGF-2 and the protease domain of FX could be disrupted in the p.F139L variant, causing destabilization of the protein. The p.E142K variant was predicted to have less impact on FX structure. In vitro expression results further supported plasma findings.
CONCLUSION: We report a new FX variant, p.F139L, causing a type I FX deficiency associated with mild to moderate bleedings in heterozygous and compound heterozygous form. The variant causes structural changes which likely affect intracellular processing of FX.